Rajiv Gandhi Cancer Institute and Research Centre is a non-profit medical facility and research institute based in Delhi, India specialising in cancer treatment and research. It is one of the largest medical centers for cancer treatment in Asia.

During the past decade, Rajiv Gandhi Cancer Institute And Research Centre conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 12 clinical trials were completed, i.e. on average, 31.6% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 8 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rajiv Gandhi Cancer Institute And Research Centre" #1 sponsor was "Rajiv Gandhi Cancer Institute & Research Center, India" with 12 trials, followed by "Hoffmann-La Roche" with 10 trials sponsored, "Pfizer" with 9 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored and "Boehringer Ingelheim" with 3 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rajiv Gandhi Cancer Institute And Research Centre" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Actoverco" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Children's Oncology Group (COG)" with 1 trials as a collaborator and "Innogene Kalbiotech Pte. Ltd" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Rajiv Gandhi Cancer Institute And Research Centre" are "Breast Cancer" (6 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Intraocular Pressure" (2 trials), "Multiple Myeloma" (2 trials) and "Neoplasm Metastasis" (2 trials). Many other conditions were trialed in "Rajiv Gandhi Cancer Institute And Research Centre" in a lesser frequency.

Most popular intervention types in "Rajiv Gandhi Cancer Institute And Research Centre" are "Drug" (32 trials), "Other" (7 trials), "Biological" (4 trials), "Device" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Docetaxel" (3 trials), "Paclitaxel" (3 trials), "Trastuzumab" (3 trials) and "Bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Rajiv Gandhi Cancer Institute And Research Centre" are 40 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Rajiv Gandhi Cancer Institute And Research Centre". undefined are not yet recruiting, 9 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in Rajiv Gandhi Cancer Institute And Research Centre, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Rajiv Gandhi Cancer Institute And Research Centre, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 6 trials that are defined as “Not Applicable".